164 related articles for article (PubMed ID: 23696595)
21. MiR-34a expression has an effect for lower risk of metastasis and associates with expression patterns predicting clinical outcome in breast cancer.
Peurala H; Greco D; Heikkinen T; Kaur S; Bartkova J; Jamshidi M; Aittomäki K; Heikkilä P; Bartek J; Blomqvist C; Bützow R; Nevanlinna H
PLoS One; 2011; 6(11):e26122. PubMed ID: 22102859
[TBL] [Abstract][Full Text] [Related]
22. Overexpressions of microRNA-9 and microRNA-200c in human breast cancers are associated with lymph node metastasis.
Wang J; Zhao H; Tang D; Wu J; Yao G; Zhang Q
Cancer Biother Radiopharm; 2013 May; 28(4):283-8. PubMed ID: 23617747
[TBL] [Abstract][Full Text] [Related]
23. Clinicopathological implications of Tiam1 overexpression in invasive ductal carcinoma of the breast.
Li Z; Liu Q; Piao J; Hua F; Wang J; Jin G; Lin Z; Zhang Y
BMC Cancer; 2016 Aug; 16(1):681. PubMed ID: 27562113
[TBL] [Abstract][Full Text] [Related]
24. DNA methylation mediated silencing of microRNA-874 is a promising diagnosis and prognostic marker in breast cancer.
Zhang L; Yan DL; Yang F; Wang DD; Chen X; Wu JZ; Tang JH; Xia WJ
Oncotarget; 2017 Jul; 8(28):45496-45505. PubMed ID: 28525377
[TBL] [Abstract][Full Text] [Related]
25. Increased expression of microRNA-301a in nonsmall-cell lung cancer and its clinical significance.
Shi YK; Zang QL; Li GX; Huang Y; Wang SZ
J Cancer Res Ther; 2016; 12(2):693-8. PubMed ID: 27461635
[TBL] [Abstract][Full Text] [Related]
26. miRNA expression in breast cancer varies with lymph node metastasis and other clinicopathologic features.
Wang B; Li J; Sun M; Sun L; Zhang X
IUBMB Life; 2014 May; 66(5):371-7. PubMed ID: 24846313
[TBL] [Abstract][Full Text] [Related]
27. MicroRNA miR-21 overexpression in human breast cancer is associated with advanced clinical stage, lymph node metastasis and patient poor prognosis.
Yan LX; Huang XF; Shao Q; Huang MY; Deng L; Wu QL; Zeng YX; Shao JY
RNA; 2008 Nov; 14(11):2348-60. PubMed ID: 18812439
[TBL] [Abstract][Full Text] [Related]
28. High miR-21 expression in breast cancer associated with poor disease-free survival in early stage disease and high TGF-beta1.
Qian B; Katsaros D; Lu L; Preti M; Durando A; Arisio R; Mu L; Yu H
Breast Cancer Res Treat; 2009 Sep; 117(1):131-40. PubMed ID: 18932017
[TBL] [Abstract][Full Text] [Related]
29. Overexpression of TNFAIP8 is associated with tumor aggressiveness and poor prognosis in patients with invasive ductal breast carcinoma.
Xiao M; Xu Q; Lou C; Qin Y; Ning X; Liu T; Zhao X; Jia S; Huang Y
Hum Pathol; 2017 Apr; 62():40-49. PubMed ID: 28087477
[TBL] [Abstract][Full Text] [Related]
30. miR-1290 and its potential targets are associated with characteristics of estrogen receptor α-positive breast cancer.
Endo Y; Toyama T; Takahashi S; Yoshimoto N; Iwasa M; Asano T; Fujii Y; Yamashita H
Endocr Relat Cancer; 2013 Feb; 20(1):91-102. PubMed ID: 23183268
[TBL] [Abstract][Full Text] [Related]
31. ATM down-regulation is associated with poor prognosis in sporadic breast carcinomas.
Bueno RC; Canevari RA; Villacis RA; Domingues MA; Caldeira JR; Rocha RM; Drigo SA; Rogatto SR
Ann Oncol; 2014 Jan; 25(1):69-75. PubMed ID: 24285016
[TBL] [Abstract][Full Text] [Related]
32. Expression of microRNA-142-3p in cervical cancer and its correlation with prognosis.
Li M; Li BY; Xia H; Jiang LL
Eur Rev Med Pharmacol Sci; 2017 May; 21(10):2346-2350. PubMed ID: 28617557
[TBL] [Abstract][Full Text] [Related]
33. Clinical potential of miR-940 as a diagnostic and prognostic biomarker in breast cancer patients.
Liu W; Xu Y; Guan H; Meng H
Cancer Biomark; 2018; 22(3):487-493. PubMed ID: 29843213
[TBL] [Abstract][Full Text] [Related]
34. High expression of gabarapl1 is associated with a better outcome for patients with lymph node-positive breast cancer.
Berthier A; Seguin S; Sasco AJ; Bobin JY; De Laroche G; Datchary J; Saez S; Rodriguez-Lafrasse C; Tolle F; Fraichard A; Boyer-Guittaut M; Jouvenot M; Delage-Mourroux R; Descotes F
Br J Cancer; 2010 Mar; 102(6):1024-31. PubMed ID: 20197771
[TBL] [Abstract][Full Text] [Related]
35. MicroRNA-30a inhibits cell migration and invasion by downregulating vimentin expression and is a potential prognostic marker in breast cancer.
Cheng CW; Wang HW; Chang CW; Chu HW; Chen CY; Yu JC; Chao JI; Liu HF; Ding SL; Shen CY
Breast Cancer Res Treat; 2012 Aug; 134(3):1081-93. PubMed ID: 22476851
[TBL] [Abstract][Full Text] [Related]
36. microRNA-944 overexpression is a biomarker for poor prognosis of advanced cervical cancer.
Park S; Kim J; Eom K; Oh S; Kim S; Kim G; Ahn S; Park KH; Chung D; Lee H
BMC Cancer; 2019 May; 19(1):419. PubMed ID: 31060525
[TBL] [Abstract][Full Text] [Related]
37. A comprehensive clinicopathological evaluation of the differential expression of microRNA-331 in breast tumors and its diagnostic significance.
Papadopoulos EI; Papachristopoulou G; Ardavanis A; Scorilas A
Clin Biochem; 2018 Sep; 60():24-32. PubMed ID: 30063890
[TBL] [Abstract][Full Text] [Related]
38. [Expression of microRNA-152 in colorectal cancer and its relationship with prognosis].
Wang Y; Yuan W; Ma X; Ma J
Zhonghua Zhong Liu Za Zhi; 2016 Oct; 38(10):763-766. PubMed ID: 27784461
[No Abstract] [Full Text] [Related]
39. Low levels of serum miR-99a is a predictor of poor prognosis in breast cancer.
Li J; Song ZJ; Wang YY; Yin Y; Liu Y; Nan X
Genet Mol Res; 2016 Aug; 15(3):. PubMed ID: 27706621
[TBL] [Abstract][Full Text] [Related]
40. miR‑425‑5p is associated with poor prognosis in patients with breast cancer and promotes cancer cell progression by targeting PTEN.
Xiao S; Zhu H; Luo J; Wu Z; Xie M
Oncol Rep; 2019 Dec; 42(6):2550-2560. PubMed ID: 31638259
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]